NCT06297369View on ClinicalTrials.gov

Evaluation of the Effect of N-acetylcysteine in Preventing Cisplatin-Induced Toxicities in Cancer Patients

PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

February 1, 2024

Primary Completion Date

February 1, 2025

Study Completion Date

August 1, 2025

Conditions
Cisplatin Adverse ReactionCisplatin NephrotoxicityCisplatin Induced Peripheral NeuropathyCancer PatientsCisplatin Ototoxicity
Interventions
DRUG

N acetyl cysteine

N-acetylcysteine 600 mg twice daily (acetylcystein ® 600 mg effervescent instant granules sachets, Sedico, Egypt)

Trial Locations (1)

Unknown

RECRUITING

Department of Clinical Oncology and Nuclear Medicine, Ain Shams University Hospitals, Cairo, Egypt., Cairo

All Listed Sponsors
lead

Ain Shams University

OTHER